NCT05476354View on ClinicalTrials.gov

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

April 3, 2023

Study Completion Date

June 13, 2023

Conditions
Essential Hypertension
Interventions
DRUG

Irbesartan/Amlodipine low

Irbesartan/Amlodipine low once daily for 8 weeks

DRUG

Irbesartan/Amlodipine high

Irbesartan/Amlodipine high once daily for 8 weeks

DRUG

Irbesartan

Irbesartan once daily for 8 weeks

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY

NCT05476354 - Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients | Biotech Hunter | Biotech Hunter